

Analysis of Dose-Distribution in Left-Lung and Heart as Increasing the Number of Beams in Left-Sided Breast Irradiation

Mohammad Shahnawaj Ansari^{1,3*}, Mohammad Ziyauddin Khan¹, Sunil Dutt Sharma², Neha Yadav^{3,4}, Mukesh Kumar Zope⁵

1. Dr. C.V. Raman University, Kota, Bilaspur, (C.G.), India
2. Bhabha Atomic Research Centre, Mumbai, India
3. Apollo Hospitals Bilaspur (C.G.), India
4. Applied Physics Department, Amity University Gwalior (M.P.), India
5. Indira Gandhi Institute of Medical Science, Patna, Bihar, India

ARTICLE INFO

Article type:
Original Paper

Article history:
Received: Jan22, 2022
Accepted: Mar10, 2022

Keywords:
Breast Cancer
Beam
Irradiation
IMRT
Planning Target Volume

ABSTRACT

Introduction: Breast cancer has been a leading malignancy in women across the globe. In breast conserving treatment, radiation therapy plays an important role. This is clinically approved that breast conserving surgery followed by adjuvant radiation therapy produces as the same survival rate as radical breast RT. The aim of this study was to find out suitable number of IMRT fields to treat left-sided breast cancer and analyze the effects of increasing the number of fields in IMRT plans.

Material and Methods: We selected 105 patients retrospectively for this study diagnosed with left-sided breast cancer of age ranging from 33 to 74 years. There were 52 cases of chest wall (CW) irradiation including SCF, 20 cases of BCS and 33 cases were of CW including supra-clavicular fossa (SCF) and internal mammary lymph nodes (IMLN).

Results: Our main objective was to analyze dose-distribution of left lung. Monitor Units (MUs) were also recorded and found almost same in these three modalities ranging from 1200 to 2000. The mean value of $V_{20Gy}(cc)$ in 11-bIMRT technique was found less by 8-17cc as compared to 7- and 9-bIMRT technique. It was observed that 11-bIMRT technique yielded slightly better outcomes in terms of $V_{20Gy}(cc)$.

Conclusion: The technique 7-bIMRT gives slightly better result in controlling low-dose volume of underlying lung and heart. As the number of IMRT beams increases, it translates into better outcomes in terms of reducing high-dose volume as well as mean-dose of left lung. So, it is prudent to use 'N' number of IMRT fields such as $7 \leq N \leq 11$ in left breast RT.

► Please cite this article as:

Ansari MS, Khan MZ, Sharma SD, Yadav N, Zope MK. Analysis of Dose-Distribution in Left-Lung and Heart as Increasing the Number of Beams in Left-Sided Breast Irradiation. Iran J Med Phys 2024; 21: 1-7.10.22038/IJMP.2023.62866.2071.

Introduction

There are various types of breast cancer, but the most common are ductal carcinoma in situ (DCIS) and invasive carcinoma. This is the most common malignancy which occurs frequently in females [1-6] and fast-growing disease in the world. In breast conserving treatment, radiation therapy (RT) plays a vital role. This is clinically approved that breast conserving surgery (BCS) followed by adjuvant radiation therapy produces as the same survival rate as radical breast surgery [7,8].

Many modern techniques have been developed within few decades to deliver dose with accuracy to the tumor with minimal damage of surrounding organs. Several studies recently reported that Intensity-Modulated Radiotherapy (IMRT) has advantage over 3D-CRT in terms of dose-conformity, homogeneity and sparing of normal organs [9-15]. IMRT needs an advanced computer program to calculate radiation dose accurately in three dimensions, based on the tumor's geometry and

location. This technique modulates the intensity of the radiation beams around the breast-tumor, and spare normal organs in the surrounding of the tumor. The IMRT technique customizes the radiation dose as per exact geometrical shape of the tumor. In contrast, it increases integral dose to normal tissues, may cause second malignancy in long-term survivors. Half beam block (HBB) technique is also found useful in sparing heart and ipsi-lateral lung in left-sided breast irradiation. The major advantage of HBB is that contra-lateral lung and breast receive minimal dose [16]. Many clinical trials have been conducted in conjunction with adjuvant breast RT resulting smaller recurrence and higher long-term survival rate [17-19]. Though radiation therapy has beneficial effects, but it may cause side effects on surrounding normal tissue. In left-sided breast RT, not only heart, but left lung also receives significant radiation dose. However, radiotherapy for breast cancer has been a challenging and rapidly growing treatment modality. Regional

*Corresponding Author: Tel: +919914714716; Email: ansarisnz05@gmail.com

lymph node irradiation in younger trials with good target coverage shows reduction in long-term toxicity causing minor benefits in overall survival rate [20-22].

Many advance techniques have been developed recently in radiation therapy with aim to increase conformity and homogeneity of dose to tumor, and simultaneously sparing normal organs [23-28]. Various research papers showed that post-operative radiotherapy reduces the rate of local recurrence significantly. It also improves the long-term survival rate on the cost of morbidity of ipsi-lateral lung [29,30]. Lung is a very important organ which remains at risk during breast RT which may cause rise of contingency of pneumonitis [31, 32].

The aim of this study was to find out suitable number of beams to treat left-breast, and to analyze the effects of increasing the number of IMRT beams on dose-distribution.

Materials and Methods

Patients, targets delineation and treatment planning

We selected 105 patients retrospectively for this study diagnosed with left-sided breast cancer age ranging from 33 to 74 years. There were 52 cases of chest wall (CW) irradiation including SCF, 20 cases of BCS and 33 cases were of CW including supra-

clavicular fossa (SCF) and internal mammary lymph nodes (IMLN). The treatment characteristics were recorded and tabulated in Table 1.

CT simulation was done for each patient in supine position with both arms positioned above his head. A copper wire also placed around the breast tissue for marking purpose which help at the time of target contouring. CT scans were taken from neck to lower abdomen, slice thickness of 3 mm. Planning target volume (PTV) as well as organs at risk (OARs) such as heart, ventricles, right breast, contra-and ipsi-lateral lungs were delineated as per Radiation Therapy Oncology Group (RTOG) guidelines for adjuvant radiotherapy of breast cancer [33, 34]. Portal dosimetry was performed of each plan before executing over patients.

We created three types of IMRT plans for each patient using 7, 9 and 11beams. Each plan was generated using eclipse planning system, version 11.0(Varian Medical System, Palo, USA). Beams were deployed at particular angle in each modality and it was tabulated in table 2.

Collimator angle was '0' degree in each plan. Beam and collimator angles remained unaltered in each technique. Beam isocenter was placed at depth 2-4cm from skin, demonstrated in figure1.

Table1. Treatment characteristics of 105 patients

n=105/ treatment site	7b-IMRT	9b-IMRT	11b-IMRT	Median Age
CW+SCF, n=52	0	10	42	57
BCS, n=20	2	3	7	48
CW+SCF+IMLN, n=33	0	4	29	54

CW= Chest wall, SCF= Supra-Clavicular Fossa, IMLN= Internal Mammary Lymph Node

Table 2. Gantry angle (in degree) in each technique

7-Beam IMRT	9-Beam IMRT	11-Beam IMRT
5-10	5-10	5-10
25-30	25-30	20-25
80-85	80	50-55
100-105	100-105	90-95
125-130	120	115
315-320	130-135	135-140
300-305	305	150
....	320	300-305
....	350-355	325-330
....	340
....	350-355




Figure 1. Displaying the position of beam's isocenter in coronal, sagittal and transverse plane.

Dose Reporting

The dose was prescribed 40.05Gy in 15 fractions (2.67Gy per fraction) for each patient considered under this study. Each plan was optimized with aim to achieve at least 95-100% dose coverage (of prescribed dose) to 100% target’s volume. Dose-constraints were almost same for OARs in each case. However, some extra precautions were taken during the plan optimization for reducing the mean-dose of underlying lung, and few minor adjustments were also done in ‘Priority’ of OARs and PTV.

After completion of the optimization, we analyzed each plan for target’s coverage ($D_{95\%}$), dose homogeneity, conformity of dose to targets and global maximum dose, which are tabulated in table 3.

For analyzing the ipsi-lateral lung dose distribution, we have considered six parameters like $V_{5Gy}(cc)$, $V_{20Gy}(cc)$, $V_{25Gy}(cc)$, $D_{50\%}(Gy)$, $D_{67\%}(Gy)$ and *mean-dose*, and it was tabulated in table 4.

In addition, $D_{100\%}(Gy)$ of ipsi-lateral lung is also recorded and graphically displayed in figure 2.

The parameters like mean, maximum, and minimum of ‘mean doses’ of contra-lateral lungs, contra-lateral breast and heart were also analyzed. These parameters were tabulated in table 5.

We have considered 7Gy as minimum dose to analyze dose dumping and low-dose volume of left lung. This is displayed in figure (3) along with DVH of ipsi-lateral lung and PTV.

Table 3. $D_{95\%}$, Global maximum dose, CI and HI for left-sided breast PTV

	$D_{95\%}(Gy)$			Global max dose (%)			HI			CI		
	7-bIMRT	9-bIMRT	11-bIMRT	7-bIMRT	9-bIMRT	11-bIMRT	7-bIMRT	9-bIMRT	11-bIMRT	7-bIMRT	9-bIMRT	11-bIMRT
Max	38.60	39.24	39.57	117.20	115.56	115.43	1.22	1.18	1.16	1.09	1.06	1.05
Min	37.07	38.06	38.04	108.62	107.57	107.40	1.13	1.11	1.08	0.94	0.95	0.98
Mean	37.99	38.55	38.79	111.98	112.05	109.52	1.16	1.14	1.11	1.04	1.03	1.01

Max = Maximum, Min = Minimum, HI = Homogeneity Index, CI = Conformity Index

Table 4. Dose-distribution details of different parameters of ipsilateral lung

Mean Dose(Gy)	Left Lung								
	$V_{5Gy}(cc)$			$V_{20Gy}(cc)$			$V_{25Gy}(cc)$		
	7-bIMRT	9-bIMRT	11-bIMRT	7-bIMRT	9-bIMRT	11-bIMRT	7-bIMRT	9-bIMRT	11-bIMRT
Max	17.03	16.86	16.97	Max 1068.60	1057.70	1073.20	Max 307.00	300.96	297.20
Min	9.33	8.83	8.74	Min 373.40	354.56	363.38	Min 74.53	58.69	45.25
ρ	12.87	12.62	11.52	ρ 638.76	687.59	690.31	ρ 181.70	173.27	164.67
	$D_{50\%}(Gy)$			$D_{67\%}(Gy)$			$D_{100\%}(Gy)$		
	7-bIMRT	9-bIMRT	11-bIMRT	7-bIMRT	9-bIMRT	11-bIMRT	7-bIMRT	9-bIMRT	11-bIMRT
Max	229.6	223.29	211.69	Max 12.51	11.98	11.75	Max 8.91	9.00	9.90
Min	35.89	29.64	23.07	Min 6.95	6.58	6.30	Min 4.77	4.60	5.30
ρ	123.12	117.64	108.68	ρ 9.81	9.40	9.05	ρ 6.94	6.78	7.36

ρ : Mean of mean dose, Max: Maximum mean dose, Min: Minimum mean dose




Figure 2. Displaying maximum, minimum and mean value of $D_{100\%}(Gy)$ of ipsilateral lung

Table 5. Details of mean dose of contra-lateral lung, contra-lateral breast and heart

	Contra-lateral Lung			Contra-lateral Breast			Heart				
	Mean Dose(Gy)			Mean Dose(Gy)			Mean Dose(Gy)				
	7-Beam	9-Beam	11-Beam	7-Beam	9-Beam	11-Beam	7-Beam	9-Beam	11-Beam		
Max	4.28	4.05	4.81	Max	5.09	5.77	5.10	Max	10.47	10.32	10.83
Min	1.96	0.87	1.97	Min	1.40	1.26	1.70	Min	4.70	4.80	5.30
ρ	3.07	2.79	3.46	ρ	3.31	3.30	3.37	Mean	8.82	6.74	6.54

ρ : Mean of mean dose , Max : Maximum mean dose , Min: Minimum mean dose




Figure 3. Dose distribution in each treatment modality along with DVH of PTV and left lung

Results

In this study, ipsi-lateral lung, contra-lateral lung, contra-lateral breast, and heart were considered as OARs during the irradiation of left-sided breast. Our main objective was to analyze dose-distribution of left lung. Monitor Units (MUs) were also recorded and found almost same in these three modalities ranging from 1200 to 2000.

Left-Lung Dose Analysis:

Few major differences were observed in the parameters analyzed here, especially in mean doses, among these three techniques. The mean value of $V_{20Gy}(cc)$ in 11-bIMRT technique was found less by 8-17cc as compared to 7- and 9-bIMRT technique. It was observed that 11-bIMRT technique yielded slightly better outcomes in terms of $V_{20Gy}(cc)$.

$V_{5Gy}(cc)$: The lowest-mean value of this parameter was 638.76cc found in 7-bIMRT technique, whilst highest-mean value was 690.31cc in 11-bIMRT modality. Maximum value was 1073.20cc recorded in 11-bIMRT technique. The lowest-minimum value was 354.56 cc recorded in 9-bIMRT. Comparatively, 7-bIMRT technique

showed slightly good result in reducing low-dose volume of 5Gy.

$V_{20Gy}(cc)$: In 11-bIMRT plan, maximum, minimum, and mean value of parameter V_{20Gy} were recorded as 297.2cc, 45.25cc and 164.67cc respectively. The highest value of this parameter was 307.00cc founding 7-bIMRT plan. The highest-mean value of this parameter was 181.70cc noted in 7-bIMRT technique. In 9-bIMRT plan, mean value was found 173.22cc. The minimum value of $V_{20Gy}(cc)$ was 45.25cc recorded in 11-bIMRT technique.

$V_{25Gy}(cc)$: Maximum values of V_{25Gy} were recorded 229.6 cc, 223.29cc, and 211.69 cc in 7-, 9- and 11-bIMRT plans respectively. Lowest-mean value of this parameter was 108.68cc found in 11-bIMRT plan. Highest-mean value was 123.12 cc observed in 7-bIMRT. In 9-bIMRT, mean value of V_{25Gy} was 117.64cc while minimum value was 29.64cc. Lowest volume of this parameter was 23.07cc found in 11-bIMRT plan.

$D_{50\%}(Gy)$: The lowest-mean value of $D_{50\%}$ was 9.05Gy found in 11-bIMRT plan. The highest maximum value was 12.51Gy observed in 7-bIMRT plan, while minimum value was 6.30Gy founding 11-bIMRT plan. In view of this parameter, no significant difference was noted among these three techniques. However, 11-bIMRT technique yielded

comparatively good outcomes in term of reducing dose to 50% volume of left lung.

D67% (Gy): The highest-mean value of $D_{67\%}$ was 7.36 Gy found in 11-bIMRT while lowest was 6.94 in 7-bIMRT technique. Maximum value of this parameter was 9.90Gy recorded in 11-bIMRT and lowest- minimum value was 4.60Gy observed in 9-bIMRT plan. Lowest value of maximum dose of $D_{67\%}$ was 8.91Gy found in 7-bIMRT technique, whilst minimum value was 4.77Gy. The modality 7-bIMRT yielded slightly better results as compared to 11-bIMRT in terms of reducing dose to $D_{67\%}$.

Mean Dose (Gy): Highest value of mean-dose was 17.03Gy recorded in 7-bIMRT plan. Lowest value of mean dose was 8.74Gy found in 11-bIMRT plan. Minimum value of mean doses was 11.52 observed in 11-bIMRT plan. Maximum and minimum values of mean-dose were found 16.86 Gy and 9.03 Gy respectively in 9-bIMRT plan. The technique 11-bIMRT produces slightly good impacts in respect of *mean-dose* as compared to 7-bIMRT and 9-bIMRT technique.

Heart Dose Analysis: Maximum values of mean doses were found approximately same in each technique. Heart's *mean dose* in 9-bIMRT and 11-bIMRT techniques were noted almost equal like 6.74Gy and 6.54Gy respectively while that of 7-bIMRT was 8.82Gy. In 11-bIMRT technique, mean-dose was recorded less by 2.28Gy as compared to 9-bIMRT and 7-bIMRT. It was observed that 11-bIMRT technique was able to reduce dose by 1.24 - 1.70Gy to 5-10cc volume of the heart. In the view of heart's mean-dose, 11-bIMRT technique yielded good results as compared to others.

Contra-lateral Lung Dose Analysis: IMRT technique with 9 beams showed comparatively better result in terms of mean dose. Maximum, minimum and mean-dose were found 4.05 Gy, 0.86Gy and 2.79Gy respectively.

Contra-lateral Breast Dose Analysis: There was no significant difference found among these techniques in terms of contra-lateral breast dose. The mean dose was observed as 3.31Gy, 3.30Gy and 3.37Gy in 7-,9- and 11-bIMRT techniques respectively.

PTV Dose Analysis: The maximum values of $D_{95\%}$ were found as 38.62Gy, 39.24Gy and 39.58Gy in 7-,9- and 11-bIMRT techniques respectively. Highest mean dose was recorded as 38.78Gy in 11-bIMRT plan, whilst minimum mean-dose was 38.06Gy in 7-bIMRT plan. Lowest global maximum dose was found 115.10% in 9-bIMRT plan.

Discussion

The study was designed to access the variation in dose-distribution in the treatment of left-breast on account of increasing the number of beams in IMRT modality. For this purpose, patients diagnosed with left-sided breast cancer were considered under this study. Our medical physicist team surveyed 563 studies related to randomize controlled trials of IMRT in conservatively resected breast carcinoma. Many studies reported multiple benefits of IMRT modality particularly in terms of normal tissue sparing effect and toxicity [35-37], and

it partially enhances cosmetic effects, too [38,39]. Several studies showed that surviving rate in breast cancer is increasing nowadays on account of early detection, social awareness and modern approach of treatment modality. Moreover, the toxicity of different kind of agents like doxorubicin and trastuzumab, plays influential role in patient's surviving rate. In left-sided breast irradiation, the important organs which remain at risk (OARs) are left lung and heart. Clinically, it is observed that acute radiation pneumonitis may be evolved in patients within six months of exposure to doses ≥ 8 Gy of radiation which can be lethal.

This can be divided into three phases (i) Latent period lasting up to 4 weeks, (ii) Exudative phase (3-8 weeks), and (iii) Acute pneumonitis phase between two and six months. The latter is an inflammatory reaction with intra-alveolar and septal edema accompanied by epithelial and endothelial desquamation. The primary response of the lung to irradiation is an increase in

micro-vascular permeability. Pulmonary fibrosis is a late-effect of irradiation, which is clinically and experimentally proved, while fibrosis may not be entirely separate from early pneumonitis.

Several studies reported that the risk of subsequent ischemic events is proportional to mean dose of the heart [40]. Normally, breast cancer survivors who underwent radiation therapy have risk of pneumonitis and long-term cardiac complications. Cardiac vascular damage may be severe mortality threat rather than breast cancer in elderly women [41].

In our study, when number of beams increases from 7 to 11, the volume of V_{20Gy} (cc) and V_{25Gy} (cc) of ipsi-lateral lung gradually decreases. But, the value of $D_{50\%}$ (Gy) of ipsi-lateral lung slightly increases. The modality 9-bIMRT yields comparatively better result in reducing the dose to 2/3rd volume of ipsi-lateral lung, and resultantly it reduces the risk of pneumonitis.

Minor differences were observed in mean dose and maximum dose of contra-lateral lung. PTV dose coverage was found almost same in these three treatment modalities. The modality of treatment named Deep Inspiration Breath Hold (DIBH) in irradiation of left reconstructed chest wall and regional nodes shows significant advantages in reducing dose to ipsi-lateral lung and underlying heart. The IMRT treatment modality with 11 beams provided almost as the same result as DIBH in terms of left lung dose and mean heart dose (MHD).

The dose conformity of PTV with higher number of beams is slightly increased low-dose exposure of normal tissues around the tumor. This may enhance slightly the risk of second malignancies and raise a question on using newer methods compared to conventional 3D-CRT. But, the high-dose volume in 3D-CRT is reported wider as compared to IMRT. In this respect, the modality 11-bIMRT shows advantage over 3D-CRT.

The study shows that 11-bIMRT can reduce the dose of volumes V_{20Gy} (cc) and V_{25Gy} (cc) up to clinically acceptable level, and it also reduces the mean dose of left lung. Hence, increasing number of IMRT beams (7-

11 beams) shows an advantage in reducing mean dose, volume of $V_{20Gy}(cc)$ and $V_{25Gy}(cc)$ of ipsilateral lung. The technique 7-bIMRT is able to reduce low dose volume of underlying lung.

Conclusion

These days, IMRT modality is frequently used in left-sided breast irradiation to reduce mean-dose and high-dose volume of ipsi-lateral lung. The technique 7-bIMRT gives slightly better result in controlling low-dose volume of underlying lung and heart. However, 11-bIMRT treatment technique provides relatively better results in reducing high-dose volume and mean-dose of left lung along with MHD. As the number of IMRT-beam increases, it translates into better outcomes in terms of reducing high-dose volume as well as mean-dose of left-lung. So, the study advises us to use 'N' number of IMRT fields such as $7 \leq N \leq 11$ in left-sided breast RT.

Acknowledgment

The authors are very much thankful to Dr. Manoj Nagpal (Unit Head, Apollo Hospitals Bilaspur, Chhattisgarh, India) as he provided all facilities to accomplish this brilliant research work within time frame.

References

1. Simonetto C, Eidemüller M, Gaasch A, Pazos M, Schönecker S, Reitz D, et al. Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. *Radiotherapy and Oncology*. 2019 Feb 1;131:202-7.
2. Kaidar-Person O, Offersen BV, Poortmans P. Should risk-adapted delineation considered de-escalation of therapy? The ESTRO-ACROP radiation therapy guidelines after implant-based immediate reconstruction for early stage breast cancer. *Radiother Oncol*. 2019;141:327-8.
3. Schönecker S, Walter F, Freisleder P, Marisch C, Scheithauer H, Harbeck N, et al. Treatment planning and evaluation of gated radiotherapy in left-sided breast cancer patients using the Catalyst TM/Sentinel TM system for deep inspiration breath-hold (DIBH). *Radiation oncology*. 2016 Dec;11:1-0.
4. Trivedi SJ, Choudhary P, Lo Q, Sritharan HP, Iyer A, Batumalai V, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. *Radiotherapy and Oncology*. 2019 Mar 1;132:148-54.
5. Cai G, Cao L, Kirova YM, Feng Y, Chen JY. Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer. *Radiat Oncol*. 2019;14:115.
6. Haussmann J, Budach W, Tamaskovics B, Bölke E, Corradini S, Djiepmo-Njanang FJ, et al. Which target volume should be considered when irradiating the regional nodes in breast cancer? Results of a network-meta-analysis. *Radiation Oncology*. 2019 Dec;14:1-4.
7. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med*. 2002;347: 1227-32.
8. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *New Engl J Med*. 2002; 347: 1233-41.
9. Njeh CF, Saunders MW, Langton CM. Accelerated partial breast irradiation using external beam conformal radiation therapy: a review. *Crit Rev Oncol Hematol*. 2012; 81: 1-20.
10. Hille-Betz U, Vaske B, Michael Bremer MD, Philipp Soergel MD, Kundu S, Klapdor R, et al. Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. *Strahlentherapie und Onkologie*. 2016;192(1):8.
11. Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). *Radiother Oncol*. 2010; 94: 264-73.
12. Coles CE, Brunt AM, Wheatley D, Mukesh MB, Yarnold JR. Breast radiotherapy: less is more? *Clin Oncol (R Coll Radiol)*. 2013; 25: 127-34.
13. Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase-3 randomised controlled trial. *Eur J Cancer*. 2015; 51: 451-63.
14. Arthur DW, Vicini FA. Accelerated partial breast irradiation as a part of breast conservation therapy. *J Clin Oncol*. 2005; 23: 1726-35.
15. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). *J Am Coll Surg*. 2009; 209:269-77.
16. Ansari S, Kumar Satpathy S. Half Beam Block Technique in Breast Cancer and It's Dosimetric Analysis using different Algorithms. *Iran J Med Phys*. 2017; 14: 66-74.
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death. Meta-analysis of individual patient data for 10 801 women in 17 randomized trials. *Lancet*. 2011;378(9804):1707-16.
18. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005 Dec 17;366(9503):2087-106.

- doi: 10.1016/S0140-6736(05)67887-7. PMID: 16360786.
19. Overgaard M, Jensen MB, Overgaard J, Hansen P, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen. Danish breast Cancer cooperative group/DBCG 82c randomized trial. *Lancet*. 1999;353(9165):1641–8.
 20. Darby S, Ewertz M, McGale P, Bennet A, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breastcancer. *N Engl J Med*. 2013;368(11):987–98.
 21. Darby S, McGale P, Taylor C, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer. Prospective cohort study of about 300,000 women in US SEER cancer registries. *Lancet Oncol*. 2005;6(8):557–65.
 22. Vicini F, Sharpe M, Kestin L, Martinez A. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys*. 2002;54:1336–44.
 23. Kestin LL, Sharpe MB, Frazier RC, Vicini FA, Yan D, Matter RC, et al. Intensity modulation to improve dose uniformity with tangential breast radiotherapy: initial clinical experience. *International Journal of Radiation Oncology* Biology* Physics*. 2000 Dec 1;48(5):1559–68.
 24. Ha B, Suh HS, Lee J, Lee KJ, Lee R, Moon BI. Long-term results of forward intensity-modulated radiation therapy for patients with early-stage breast cancer. *Radiat Oncol J*. 2013;31(4):191–8.
 25. Mukesh B, Barnett GC, Wilkinson JS, Moody AM, Wilson C, Dorling L, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer. 5-year results confirm superior overall cosmesis. *J Clin Oncol*. 2013;31(36):4488–95.
 26. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. *Lancet*. 2011;378(9804):1707–16.
 27. Hoening MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst*. 2007;99(5):365–75.
 28. Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. *Br J Cancer*. 2013;108(1):179–82.
 29. Morgan EA, Kozono DE, Wang Q, Mery CM, Butrynski JE, Baldini EH, et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. *Ann Surg Oncol*. 2012;19(12):3801–8.
 30. Paszat LF, Mackillop WJ, Groome PA, Schulze K, Holowaty E. Mortality from myocardial infarction following post lumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. *Int J Radiat Oncol Biol Phys*. 1999;43(4):755–62.
 31. Nielsen M, Berg M, Pedersen A, Andersen K, Glavicic V, Jakobsen E, et al. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer. National guidelines and contouring atlas by the Danish breast Cancer cooperative group. *Acta Oncol* (Stockholm, Sweden). 2013;52(4):703–10.
 32. Radiation therapy oncology group. Breast cancer atlas for radiation therapy planning: consensus definitions. 2009. Available from: <http://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx>.
 33. Meattini I, Saieva C, Marrazzo L, Di Brina L, Pallotta S, Mangoni M, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. *Breast cancer research and treatment*. 2015 Oct;153:539–47.
 34. Pignol JP, Olivetto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. *Journal of Clinical Oncology*. 2008 May 1;26(13):2085–92.
 35. Pignol JP, Truong P, Rakovitch E, Sattler MG, Whelan TJ, Olivetto IA. Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. *Radiother Oncol*. 2016;121:414–9.
 36. Mukesh MB, Qian W, Wilkinson JS, Dorling L, Barnett GC, Moody AM, et al. Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial. *Radiotherapy and Oncology*. 2014 May 1;111(2):270–5.
 37. Sardaro A, Petruzzelli MF, D'Errico MP, Grimaldi L, Pili G, Portaluri M. Radiation-induced cardiac damage in early left breast cancer patients. Riskfactors, biological mechanisms, radiobiology, and dosimetric constraints. *Radiother Oncol*. 2012;103(2):133–42.
 38. Mege A, Zioueche A, Pourel N, Chauvet B. Radiation-related heart toxicity. *Cancer Radiother*. 2011;15(6–7):495–503.
 39. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. *Circulation*. 2018 Feb 20;137(8):e30–66.
 40. Dumane VA, Saksornchai K, Zhou Y, Hong L, Powell S, Ho AY. Reduction in low-dose to normal tissue with the addition of deep inspiration breath hold (DIBH) to tangential volumetric modulated arc therapy (TVMAT) in breast cancer patients with implant reconstruction receiving regional nodal irradiation. *Radiat Oncol*. 2018;13(1):187.
 41. Dorr W, Herrmann T. Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. *Strahlenther Onkol*. 2002;178(7):357–62.